Hcmed Innovations Co

Hcmed Innovations Co Net Debt

The Net Debt of Hcmed Innovations Co (6934.TWO) as of Nov 6, 2026 is 42.09 M TWD. In the previous year, Net Debt was -166.99 M TWD — a change of -125.20% (higher).

Net Debt

42.09 MTWD

YoY

-125.20%

Last updated:

Net Debt of Hcmed Innovations Co is 2025 42.09 M TWD. Net Debt of Hcmed Innovations Co was 2024 -166.99 M TWD. It decreases by -125.20% higher compared to the previous year.

The Hcmed Innovations Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2020
-84.06 M TWD
Jan 1, 2021
-37.02 M TWD
Jan 1, 2022
-119.90 M TWD
Jan 1, 2023
-227.37 M TWD
Jan 1, 2024
-166.99 M TWD
Jan 1, 2025
42.09 M TWD
The Hcmed Innovations Co Net Debt history
YEARNet DebtYoY
42.09 MTWD-125.20%
-166.99 MTWD-26.56%
-227.37 MTWD+89.63%
-119.90 MTWD+223.89%
-37.02 MTWD-55.96%
-84.06 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hcmed Innovations Co Stock analysis

What does Hcmed Innovations Co do? Hcmed Innovations Co Ltd generates revenue through the design, development, production, and sales of handheld medical nebulizers tailored to pharmaceutical companies' requirements. The company offers vibrating mesh nebulizers that adjust oscillation frequency for effective drug delivery to the lower respiratory tract without specialized breathing techniques, targeting conditions like chronic obstructive pulmonary disease, asthma, cystic fibrosis, and respiratory infections. Additionally, Hcmed provides contract development and manufacturing organization (CDMO) services for drug-specific nebulizers, focusing on inhalation dosage form design and development. Key markets include the United States, Taiwan, Switzerland, Israel, and the United Kingdom, where pharmaceutical companies purchase these specialized medical devices and services. The company's primary products are vibrating mesh nebulizers and CDMO services for pharmaceutical clients. Vibrating mesh nebulizers are designed to deliver medications efficiently to the respiratory system, while CDMO services support the creation of nebulizers optimized for specific drugs. These offerings are sold to pharmaceutical companies seeking to enhance their inhalation therapy solutions. The United States, Taiwan, Switzerland, Israel, and the United Kingdom represent the main geographic segments driving sales, with pharmaceutical firms as the core customer base. Hcmed Innovations Co Ltd monetizes its expertise in medical device development by supplying both hardware and specialized manufacturing services. The vibrating mesh nebulizer technology enables precise drug delivery, addressing high-demand respiratory conditions. CDMO services further capitalize on the growing need for customized inhalation therapies, with pharmaceutical companies as the primary buyers. Sales are concentrated in the United States, Taiwan, Switzerland, Israel, and the United Kingdom, reflecting the global reach of its target market. Hcmed Innovations Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hcmed Innovations Co stock

Net Debt of Hcmed Innovations Co is 42.09 M TWD in 2025.

Net Debt of Hcmed Innovations Co changed from -166.99 M TWD to 42.09 M TWD, representing a -125.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Hcmed Innovations Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Hcmed Innovations Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Hcmed Innovations Co

All Key Metrics — Hcmed Innovations Co